Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies

Nicolle H. R. Litjens1*, Ling Huang1, Burç Dedeoglu1, Ruud W. J. Meijers1, Jaap Kwekkeboom2 and Michiel G. H. Betjes1

1 Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, 2 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

The absence of anti-cytomegalovirus (CMV) immunoglobulin G (IgG) is used to classify pretransplant patients as naïve for CMV infection (CMVneg patients). This study assessed whether pretransplant CMV-specific T-cell immunity exists in CMVneg patients and whether it protects against CMV infection after kidney transplantation. The results show that CMV-specific CD137+IFNγ+CD4+ and CD137+IFNγ+CD8+ memory T cells were present in 46 and 39% of CMVneg patients (n = 28) although at much lower frequencies compared to CMVpos patients (median 0.01 versus 0.58% for CD4+ and 0.05 versus 0.64% for CD8+ T cells) with a less differentiated CD28-expressing phenotype. In line with these data, CMV-specific proliferative CD4+ and CD8+ T cells were observed in CMVneg patients, which significantly correlated with the frequency of CMV-specific T cells. CMV-specific IgG antibody-secreting cells (ASC) could be detected at low frequency in 36% of CMVneg patients (1 versus 45 ASC/10⁵ cells in CMVpos patients). CMVneg patients with pretransplant CMV-specific CD137+IFNγ+CD4+ T cells had a lower risk to develop CMV viremia after transplantation with a CMV pos donor kidney (relative risk: 0.43, \( P = 0.03 \)). In conclusion, a solitary CMV-specific T-cell response without detectable anti-CMV antibodies is frequent and clinically relevant as it is associated with protection to CMV infection following transplantation with a kidney from a CMVpos donor.

Keywords: cytomegalovirus, T cells, B cells, cellular immunity, humoral immunity

INTRODUCTION

Kidney transplant (KT) recipients are at increased risk for infections following transplantation, one of the major threats being cytomegalovirus (CMV). A primary infection or reactivation with CMV may cause a viremia and can lead to severe CMV disease with organ involvement (1). Patients at increased risk for an infection with CMV either receive prophylactic or preemptive antiviral therapy (valganciclovir) following kidney transplantation (2). Classification of the risk for a CMV infection before KT is based on the presence of anti-CMV immunoglobulin G (IgG) in the patient in combination with the CMV serostatus of the kidney donor. Immunity to viruses, for example, CMV, is dependent on adequate help from CMV-specific CD4+ T cells enabling production of
neutralizing antibodies by CMV-specific B-cells/plasma blasts and effective cytotoxic CD8+ T cell (CTL) responses (3–5).

Absence of neutralizing antibodies does not necessarily imply that the antigen was not encountered before as cellular immunity might still be present. Furthermore, it is known that in end-stage renal disease (ESRD) patients protective humoral immunity is not maintained and often not achieved (6, 7). Therefore, several groups have proposed to include an evaluation of cellular immunity against CMV in the risk assessment strategy to more accurately assess sensitization before transplantation (8–10). Data are scarce as to whether the presence of limited cellular immunity protects from CMV viremia after kidney transplantation and no detailed insights into which T-cell subsets are involved in just-sufficient protection are available, as cellular immunity is mainly assessed by ELISpot (11).

T-cell differentiation can be assessed by using expression of CD45RO or CD45RA and the lymph node homing chemokine receptor CCR7 which is able to identify naive T cells and different memory T cell subsets, i.e., central memory (CM), effector memory (EM), and finally terminally differentiated EM CD45RA+ (EMRA) (12). This is accompanied by loss of the co-stimulatory receptor CCR7 which is able to identify naive T cells and differentiate CD28null T cells (13, 14). Whether presenile of limited cellular immunity to CMV impacts T-cell aging characteristics in ESRD patients is not known.

The aim of this study is to assess CMV-specific T-cell immunity including the differentiation stage of CMV-specific T cells and to determine its clinical relevance with respect to protection from CMV viremia following transplantation in a cohort of CMV-seronegative patients. Furthermore, the impact on T-cell aging parameters was evaluated.

MATERIALS AND METHODS

Study Population

In a cohort of stable CMV-seronegative and, as a control, age- and gender-matched CMV-seropositive recipients of a kidney from a CMV-seropositive donor (D+/R− and D+/R+, respectively), CMV-specific immunity was assessed before transplantation and linked to CMV viremia following KT. Most of the patients (86%) received induction therapy with basiliximab (Simulect®, Novartis). The standard triple immunosuppression given following transplantation consisted of tacrolimus (Prograf®, Astellas Pharma), mycophenolate mofetil (Cellcept®, Roche), and prednisolone (the first 3 months post-KT), the first given to 93% and the latter two to all of the patients. The first 6 months following transplantation, antiviral prophylaxis with valganciclovir 450 mg q.d. was given and if necessary adjusted for impairment of renal function. Patient characteristics are listed in Table 1. All patients gave written informed consent to participate in this study. The study was approved by the Medical Ethical Committee of the Erasmus MC (METC number 2010-080) and conducted in accordance with the Declaration of Helsinki and the Declaration of Istanbul.

Detection of CMV Viremia and CMV-Specific Antibodies

Serum IgG antibodies to CMV [expressed as arbitrary units/mL (AU/mL)] were measured with an enzyme immune assay (Biomerieux, VIDAS, Lyon, France). An outcome of ≥6 AU/mL was considered positive. Patients were monitored at a 3 months interval during the first year following transplantation with respect to presence of CMV DNA. Diagnosis of a CMV-viremic episode was based on the presence of copies [expressed in international units/mL (IU/mL)] of CMV DNA in blood and established by a quantitative polymerase chain reaction at the department of Virology at the Erasmus MC. An outcome of >50 IU/mL was indicative for a CMV viremia.

Isolation of Peripheral Mononuclear Cells (PBMCs)

Before KT, PBMCs were isolated as described in detail before (16) from heparinized blood samples drawn from CMV-seronegative

### TABLE 1 | Demographic and clinical characteristics of study population.

|                          | D+/R− (n = 14) | D+/R+ (n = 28) | P-value |
|--------------------------|---------------|---------------|---------|
| Age in yearsa,b          | 50 (19–63)    | 47.5 (21–76)  | NS      |
| Male                     | 50% (7)       | 68% (19)      | NS      |
| Cytomegalovirus (CMV) immunoglobulin G titer (AU/mL) | 47.5 (9–354) | 0.01       |
| CMV viremia              | 0%            | 46% (13)      | <0.01   |
| Time point of CMV viremia post-kidney transplant (KT) months | 5 (2–12)     |              |         |
| Renal replacement therapyb |               | NS           |         |
| – Preemptive transplantation | 43% (6)    | 43% (12)      |         |
| – Patients on dialysis   | 57% (8)       | 57% (16)      |         |
| Underlying kidney diseaseb |               | NS           |         |
| – Nephroclerosis/atherosclerosis/hypertension | 14% (2)    | 25% (7)      |         |
| – Primary glomerulopathies | 36% (5)    | 29% (8)      |         |
| – Diabetes               | 21% (3)       | 11% (8)       |         |
| – Urinary tract infections/stones | 3% (1)  | 3% (1)       |         |
| – Reflux nephropathy      | 7% (2)        |              |         |
| – Polycystic kidney disease | 29% (4)   | 22% (6)      |         |
| – Other/unknown           |               | NS           |         |
| Previous KTc             | 1             | 1             | NS      |
| Mismatches HLA class Ic  | 2 (1–4)       | 2 (0–4)       | NS      |
| Mismatches HLA class IIc | 1 (0–2)       | 1 (0–2)       | NS      |
| Immunosuppressive medication |           |              |         |
| – Basiliximab induction therapyd | 79% (11) | 89% (25)     | NS      |
| – Prednisoloned          | 100% (14)     | 100% (28)    | NS      |
| – MMFred                  | 100% (14)     | 100% (28)    | NS      |
| – Tacrolimusd            | 93% (13)      | 93% (26)     | NS      |
| – Switch tacrolimus → everolimusd | 7% (1)  | 7% (2)       | NS      |
| Donor age in yearsa,b    | 42 (27–66)    | 57 (29–72)   | <0.01   |

aMedian (min–max).

bAt pre-KT.

cGiven at day 0 and day 4 post-KT.

dGiven the first 3 months post-KT.

e6 months post-KT.

NS, not significant.
and CMV-seropositive patients and stored at 10 million PBMCs per vial at −150°C until further use.

**Detection of CMV-Specific CD137-Expressing Cytokine-Producing T Cells**

Peripheral mononuclear cells of 28 CMV-seronegative and 14 CMV-seropositive patients were thawed, allowed to rest for 8 h at 37°C and stimulated (5 × 10^6 PBMCs/mL) in RPMI-1640 containing glutamax (GibcoBRL, Paisley, Scotland) supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% heat-inactivated pooled human serum, further referred to as standard culture medium. Stimulation was performed in polystyrene tubes (BD Pharmingen, Erembodegem, Belgium) in the presence of co-stimulation CD49d (1 µg/mL; BD) without (background) or with a mixture of overlapping peptide pools covering the whole pp65 and IE-1 protein of CMV (1 µg/mL; PepTivator-CMV pp65 and IE-1; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and brefeldin A (Golgiplug; BD Pharmingen) for 12 h. This intracellular cytokine staining assay facilitates detailed characterization of CMV-specific CD4+ as well as CD8+ T cells as these can be identified by *de novo* expression of CD137 in combination with effector molecules (17). As a positive control, PBMC of 10 CMV-seronegative and 5 CMV-seropositive patients was stimulated with the combination of phorbol myristate acetate (PMA; 50 ng/mL; Sigma Aldrich, St. Louis, MO, USA) and ionomycin (1 µg/mL; Sigma Aldrich) and treated as described earlier.

Subsequently, a surface staining was performed to identify naïve (CD45RO−CCR7−) and memory T cell subsets (12). CM T cells are CD45RO+CCR7−, effector memory (EM) CD45RO−CCR7+, and terminally differentiated effector memory (EMRA) CD45RO−CCR7+. In addition, less and more differentiated T cell subsets were also identified by CD28 (i.e., less differentiated being CD28+ and more differentiated, lacking CD28, referred to as CD28null). The following monoclonal antibodies were used: brilliant violet (BV)-510-labeled anti-CD4 (Biolegend Europe BV, Uithoorn, The Netherlands), pacific blue-labeled anti-CD8 (BD, Erembodegem, Belgium), allophycocyanin-Cy7 (APC-Cy7)-labeled anti-CD8 (BD, Erembodegem, Belgium), peridinin chlorophyll-Cy5.5 (PerCP-Cy5.5)-labeled anti-CD28 (BD), and phycoerythrin-Cy7 (PE)-Cy7-labeled anti-CCR7 (BD). Following fixation and permeabilization, cells were stained intracellular using APC-labeled anti-CD137 (BD) and PE-labeled anti-IFNγ (BD Pharmingen). IL-2-producing cells were only evaluated in a fraction of the patients tested, i.e., 12 CMV-seronegative and 6 CMV-seropositive patients by co-staining intracellular using fluorescein isothiocyanate-labeled anti-IL-2 (BD). Samples were measured on the FACSNexter II (BD Pharmingen), allowing for 0.5–1 × 10^6 of T cells to be acquired, and analyzed using FACS Diva software version 6.1.2 (BD). The gating strategy for identifying CMV-specific CD137+CD4+T cells within the different subsets and in combination with cytokine production are shown in Figure S1 in Supplementary Material, a similar approach was followed for CD8+ T cells. The median (IQ range) background of CD137-expressing CD4+ T cells of all samples amounted to 0.05% (0.03–0.07%) whereas that of CD137-expressing CD8+ T cells was higher, amounting to 0.44% (0.23–1.02%).

The median background value for CD137+IFNγ+CD4+ and CD8+ and CD137+IL-2+CD4+ T cells of all samples were 0.01% (0.01–0.02%), 0.04% (0–0.09%), and 0.01% (0.01–0.01%), respectively. Most of the background signal within CD4+ T cells was observed in cells co-expressing CD28 and of a CM/EM phenotype whereas that observed for CD8+ T cells were predominantly lacking CD28 and of the EM/EMRA phenotype. Since frequencies obtained for the various parameters differed considerably amongst patients, we subtracted the unstimulated value per patient from that after CMV-peptide stimulation to calculate the net signal as shown in the results. A positive detectable CMV-specific response was identified if the net response was over 0. Only detectable CD4+ and CD8+CD137+ CMV-specific T cell responses were analyzed in more detail with respect to cytokine production and phenotypic aspects.

**Detection of CMV-Specific Proliferating T Cells**

Peripheral mononuclear cells of 12 CMV-seronegative and 6 CMV-seropositive patients were thawed and labeled with carboxyfluorescein diacetate succinimidyl ester according to the manufacturer’s instruction (CFSE; Molecular Probes®, The Netherlands) and subsequently stimulated in triplicate in standard culture medium at 5 × 10^3/well (96 wells-round bottom-shaped plate) without or with CMV-lysate (30 µg/mL; Microbix Biosystems Inc., ON, Canada) or with a mixture of overlapping peptide pools covering the whole pp65 and IE-1 protein of CMV (both at a final concentration of 1 µg/mL; PepTivator-CMV pp65 and IE-1; Miltenyi Biotec). Stimulation with CMV-lysate might allow for characterization of the total pool of CMV-specific CD4+ T cells as the overlapping peptide pools cover only two (albeit dominant) peptides of the CMV protein. Proliferation of CMV-specific CD8+ T cells was only analyzed following stimulation with overlapping peptide pools of pp65 and IE-1 and not whole CMV lysate due to their restriction with respect to length (number of amino acids) of the peptides presented in the context of HLA class I. Following 6 days, cells were harvested, stained using monoclonal antibodies directed against CD3, CD4, CD8, and CD28 (again to identify less differentiated versus more differentiated subsets amongst proliferating T cells), and dead cells were excluded using 7-aminoactinomycin D. Samples were measured on the FACSComp II (BD) and analyzed using FACS Diva software version 6.1.2 (BD), percentages of CMV-specific proliferating T cells were calculated by subtracting percentages of T cells proliferating in absence of these stimuli. The median (IQ range) of proliferating CD4+ and CD8+ T cells in absence of a stimulus amounted to 0.83% (0.50–2.48%) and 1.42% (0.69–3.36%), respectively. A positive detectable response was identified if the net response was over 0.

**Total and CMV-Specific IgG Antibody-Secreting Cells (ASC)**

Peripheral mononuclear cells of 11 CMV-seronegative and, as a positive control, 4 CMV-seropositive patients were thawed and subsequently stimulated at a density of 2 × 10^6/mL for 5 days with R848 and recombinant IL-2, according to the manufacturer’s
instruction (U-Cytech BV, Utrecht, The Netherlands). On day 4, the wells of a 96-well plate were coated overnight at 4°C according to the manufacturer’s instruction. Coating consisted of either an antihuman IgG antibody, for enumeration of total IgG ASC or CMV lysate (30 µg/mL Microbix Biosystems Inc., ON, Canada), for enumeration of CMV-specific IgG ASC. Following stimulation, cells were harvested, counted, and added to the coated ELISpot plate at different concentrations, each in triplicate. After a 7 h incubation (37°C, 5% CO2), cells were lysed and debris washed away using PBS/0.05% Tween-20. Subsequently, the wells of the ELISpot plate were incubated for 1 h at 37°C with a biotinylated antihuman IgG (detection) antibody and upon washing followed by an incubation with phi-labeled anti-biotin antibody (GABA) for 1 h at 37°C. Finally ASC were visualized, upon a washing procedure, using an activation solution (U-Cytech BV) resulting in a silver precipitate upon incubation in the dark at room temperature. Color development was stopped using di-ionized water and spots were counted using an ELISpot reader (Bioreader®-600V, BIO-SYS GmbH, Karben, Germany). CMV-IgG ASC are expressed as number/10⁶ cells and a frequency of total IgG ASC.

In addition to analyzing ASC, a sample before and following stimulation was analyzed for B cell blast formation by flow cytometry. The following panel of monoclonal antibodies was used: BV510-labeled anti-CD19 (Biolegend), BV421-labeled anti-CD27 (eBioscience). The following panel of monoclonal antibodies was used: BV510-labeled anti-CD19 (Biolegend), BV421-labeled anti-CD27 (eBioscience). Plasma blasts were CD19+CD38hi-CD27+. Relative telomere length of CD4+ and CD8+ T cells were determined using a whole-blood staining as described in detail before.

Telomere Length Assay
Relative telomere length of CD4+ and CD8+ T cells were determined by Multiwell plates with fluorescent in situ hybridization (flow-FISH) as described previously (15, 20).

Statistical Analyses
Statistical analyses were performed using GraphPad Prism version 5.01. Non-parametric Mann–Whitney U-test or Kruskal–Wallis test followed by a post hoc analysis (Dunn’s multiple comparison test). Categorical variables were compared using the Fisher’s exact test. The non-parametric Spearman rank correlation coefficient (Spearman’s rho, Rs) was used to evaluate associations between various parameters. P-values <0.05 for two sides were considered statistically significant.

RESULTS

Study Population Characteristics
The demographic and clinical characteristics of the study population are given in Table 1. Twenty-eight CMV-seronegative and 14 age- and gender-matched CMV-seropositive patients were included in this study. Both groups were well matched with no significant differences in clinical characteristics. Approximately half of the CMV-seronegative versus none of the CMV-seropositive patients experienced a CMV viremia within 12 months after transplantation (P < 0.01).

CMV-Seronegative Patients Frequently Have CMV-Specific T Cells
Cytomegalovirus-specific CD4+ and CD8+ T cells, identified by expression of CD137 upon stimulation with a peptide pool of the two immunodominant proteins pp65 and IE-1 (CD137+CD4+ and CD137+CD8+) were present in 16 out of 28 CMV-seronegative patients. Median (IQ range) values of the positive responses amounted to 0.03% (0.01–0.11%) and 0.10% (0.03–0.18%) for CD4+ and CD8+ T cells, respectively (Figures 1A,C, black dots). A positive correlation was observed between the CD4+ and CD8+ level of CMV-specific T-cell response in CMV-seronegative patients (Rs = 0.50, P < 0.05). The percentages of CMV-specific CD137-positive CD4+ and CD8+ T cells (present in 14 and 11 out of 14 CMV-seropositive patients, respectively) were significantly higher in CMV-seropositive patients and amounted to 0.61% (0.11–1.04%) and 1.45% (0.44–8.69%) (Figures 1A,C, open dots), respectively.

Cytomegalovirus-specific CD137+CD4+ and CD137+CD8+ T cells were predominantly of the memory phenotype in both CMV-seropositive as well as CMV-seronegative patients. However, significantly higher percentages (P < 0.05) of CD137+CD4+ and CD137+CD8+ T cells in CMV-seronegative patients had a naive phenotype when compared to CMV-seropositive patients (Figures 1B,D, respectively). No differences were observed when comparing the maximal capacity of T cells to express CD137 between CMV-seronegative and CMV-seropositive patients upon PMA/ionomycin stimulation (Figures S2A,B in Supplementary Material).

CMV-Specific T Cells in CMV-Seronegative Patients Produce IFNγ and IL-2
Next, the presence and distribution of IFNγ- and IL-2-producing CMV-specific T cells were studied. In 13 out of 28 CMV-seronegative patients, CMV-specific IFNγ+CD137+CD4+ T cells were present and median (IQ range) frequencies amounted to 0.01% (0.01–0.04%) versus 0.58% (0.16–0.87%) for CMV-seropositive patients, that all had CMV-specific IFNγ+CD137+CD4+ T cells (Figure 1E, P < 0.001). In CMV-seropositive patients, approximately 37% of the CMV-specific CD137+ expressing CD4+ T cells produced IFNγ compared to 69% in CMV-seropositive patients (P < 0.05). IFNγ-producing CMV-specific CD137+CD4+ T cells all co-expressed CD28, and similar frequencies were present within the CM and EM subset of CMV-seropositive patients. In CMV-seropositive patients, a slightly more differentiated phenotype was observed as 16% (P < 0.01) of these cells lacked CD28 and 75% were classified as EM T cells (Figure 1F).

In 12 CMV-seronegative and 6 CMV-seropositive patients, frequencies of IL-2-producing CD4+ T cells specific for CMV were evaluated as we have previously shown these to be associated
with anti-CMV IgG titers (6). CMV-specific CD137^+CD4^+IL-2^+ T cells were detected in 9 out of 12 (75%) of CMV-seronegative versus all of the CMV-seropositive patients and median (IQ range) frequencies amounted to 0.01% (0.01–0.01%) and 0.26% (0.01–0.87%) for CMV-seronegative and CMV-seropositive patients (P < 0.05; **Figure 1G**). Forty percent of CMV-specific CD137-expressing CD4^+ T cells of CMV-seronegative patients produced IL-2 compared to 37% in CMV-seropositive patients.

In CMV-seronegative patients almost all IL-2-producing cells co-expressed CD28, in contrast to the presence of CD28null CMV-specific IL-2-producing cells (10%) in the CMV-seropositive group (P < 0.01; **Figure 1H**).

IFN-γ-producing CD137^+CD8^+ T cells were detected in 11 out of 28 (39%) CMV-seronegative and 11 out of 14 (79%) CMV-seropositive patients. Median (IQ range) frequencies amounted to 0.05% (0.01–0.12%) and 0.64% (0.22–1.90%) within

---

**FIGURE 1** Continued
Peripheral mononuclear cells of patients were stimulated for 12-h in presence of brefeldin A and αCD49d alone or with a mixture of pp65 and IE-1 overlapping peptide pools. Subsequently, cells are cell surface and intracellular stained to determine frequencies and phenotypic characteristics of CMV-specific CD137-expressing T cells as well as those producing cytokines. CMV-specific CD137-expressing CD4+ (a) and CD8+ (c) T cells, corrected for background (αCD49d only), are depicted as a percentage of total CD4+ or CD8+ T cells and the uncorrected values are set to 100% and dissected for CD4+ (B) or CD8+ (D) T cells co-expressing or lacking CD28 and the different naive and memory T cell subsets. A similar approach is followed for CMV-specific CD137-expressing IFN-γ and IL-2-producing CD4+ (e,g) and dissection in panel (F,h) and CD8+ (i) and dissection in panel (J) T cells, respectively. Closed and open symbols/bars represent CMV-seronegative (with a detectable response) and CMV-seropositive patients, respectively, and bars depict medians and interquartile range of the patient groups. *P < 0.05; **P < 0.01, ***P < 0.001.

Only 9% of CD137-expressing CD8+ T cells produced IFNγ in CMV-seronegative versus 36% of CMV-seropositive patients (P < 0.01). The differentiation status of these cells was similar for both groups and most IFNγ+CD137+CD8+ T cells were found within the EM and highly differentiated EMRA subsets (Figure 1J). In CMV-seronegative patients, 65% of CMV-specific IFNγ-producing cells co-expressed CD28, in contrast to the presence of 89% CD28nullIFNγ-producing cells in CMV-seropositive patients (P < 0.05; Figure 1J). The frequency of CMV-specific CD137+CD8+ T cells producing IL-2 was low, i.e., median and IQ range amounted to: 0.001% (0.001–0.001%) and 0.024% (0.01–0.05%) of the total CD8+ T cells for CMV-seronegative and CMV-seropositive patients, respectively. As less than 5% of CD137-expressing CD8+ T cells produced IL-2, no further dissection into T-cell subsets was done.

The CMV-specific CD137+CD4+ and CD8+ T cells with a naive phenotype, present at higher frequencies in CMV-seronegative patients (Figures 1B,D) did not produce IL-2 (Figure 1H) or IFNγ (Figures 1E,J).

Collectively, these data show that in a substantial fraction of CMV-seronegative patients cytokine-producing cells are present within CMV-specific CD137-expressing T cells, although at lower frequencies. Similar to CMV-seropositive patients, these are mainly of the memory phenotype albeit less differentiated as they
are more CD28+. No differences were observed when comparing the maximal capacity of T cells to express CD137 (Figures S2A,B in Supplementary Material) and produce cytokines between CMV-seronegative and CMV-seropositive patients (Figures S2C–E in Supplementary Material).

CMV-Specific T Cell Proliferation in CMV-Seronegative Patients
In addition to measuring the capacity to exert effector function by producing cytokines, we evaluated CMV-specific T cell proliferation by using both CMV-lysate and the peptide pool of the immunodominant proteins pp65 and IE-1 (Figures 2A,B, typical flowcytometric example). CMV-lysate-induced proliferation was observed in 10 out of 12 CMV-seronegative KT-recipients for CD4+ T cells, respectively. Median (IQ range) percentages of proliferating CD4+ T cells amounted to 2.2.55% (0.88–7.09%) (Figure 2C). Proliferation in response to the mixture of pp65- and IE-1-overlapping peptide pools was observed in a smaller proportion of CMV-seronegative patients, i.e., 7 and 3 out of 12 KT recipients for CD4+ and CD8+ T cells [median and IQ range: 0.35 and 0.09–0.64% (Figure 2C) and 0.33 and 0.19–1.00%...
**Low Frequency of CMV-Specific IgG ASC in CMV-Seronegative Patients**

Next we evaluated whether CMV-specific memory B cells could be detected in the circulation of CMV-seronegative patients. The frequency of plasma blasts within the circulation is very low but can be induced from B cells upon polyclonal stimulation. The total B cell number and responses may be negatively affected in ESRD patients and therefore we first documented that this protocol can indeed induce plasma blasts. As shown in **Figure 3A**, plasma blasts were induced (CD27⁻CD38⁺CD19⁺, from 1.4 to 48.1%) following a 5-day polyclonal stimulation. Next, total IgG and CMV-IgG ASC were quantified by ELISpot. CMV-IgG ASC were detected above background in 4 out of 11 (36%) of CMV-seronegative patients and net median (IQ range) CMV-specific IgG ASC amounted to only 1/10⁵ (1–10¹⁰⁷), i.e., 0.08% (0.02–0.14%) of total IgG ASC (**Figures 3B, C**). All CMV-seropositive patients had detectable CMV-IgG ASC [median 45 cells/10⁵ (7–114/10⁵), 0.38% (0.11–1.70%) of total IgG ASC]. Interestingly, CMV-specific IFN-γ- as well as IL-2-producing CD137⁺CD4⁺ T cells of the total patient group (CMV-seropositive and CMV-seronegative patients) were positively correlated with numbers of CMV-specific IgG ASC (Rs = 0.52; P < 0.05 and Rs = 0.53; P < 0.05, respectively).

**CMV-Specific Immunity in CMVneg Patients**

Cytomegalovirus latency leaves a clear fingerprint on the T cell immune system. The CMV-associated changes in the circulating T cell compartment of CMV-seropositive ESRD patients comprise of a reduced telomere length, significant expansion of the CD8⁺ T cell pool and increased differentiation status of the memory T cells, notably the induction of CD28null T cells in both CD4⁺ and CD8⁺ T cells (21, 22). However, such changes were not observed when comparing CMV-seronegative patients with and without detectable CMV-specific CD137⁺-expressing IFN-γ-producing CD4⁺ T cells (**Table 2**).

**DISCUSSION**

In this study, we evaluated the presence of CMV-specific cellular and humoral immunity in a cohort of CMV-seronegative patients and assessed the clinical relevance with respect to the risk for a CMV viremia after kidney transplantation. Data revealed the presence of a low frequency of CMV-specific T cells in over half of these patients. Interestingly, in particular IFN-γ-producing CMV-specific CD4⁺ T cells were associated with protection from CMV viremia following transplantation with a kidney from a CMV-seropositive donor. Thus, a protective anti-CMV cellular immunity may exist in the absence of serum anti-CMV IgG.
TABLE 2 | Effects of CMV-immunity on T-cell parameters before transplantation.

|                      | CMV**ESRD patients (N = 14) | CMV**ESRD patients without CMV-specific CD137+IFNγ+CD4+ T cells (N = 15) | CMV**ESRD patients with CMV-specific CD137+IFNγ+CD4+ T cells (N = 13) | P-value* |
|----------------------|-----------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|----------|
| T cells              | 1,184 (887–1,519)           | 1,039 (636–1,360)                                                     | 1,057 (750–1,340)                                                     | ns       |
| CD4+ T cells         | 629 (444–786)               | 714 (373–916)                                                         | 639 (451–821)                                                         | ns       |
| CD4+ T_Mem cells     | 110 (73–173)                | 213 (119–531)                                                         | 226 (163–354)                                                         | ns       |
| CD4+ T_Em cells      | 535 (292–641)               | 385 (185–512)                                                         | 434 (255–641)                                                         | ns       |
| CD4+ T_EMRA cells    | 263 (174–389)               | 227 (137–366)                                                         | 283 (176–363)                                                         | ns       |
| CD4+ T_Naive cells   | 185 (106–301)               | 116 (100–148)                                                         | 106 (80–273)                                                         | ns       |
| CD4+ T_CD28null cells| 7 (5–21)                    | 11 (4–18)                                                             | 8 (3–13)                                                              | ns       |
| CD4+CD28null T cells | 29 (3–65)                   | 3 (2–5)                                                               | 3 (1–20)                                                              | ns       |
| CD4+CD28null T_mem   | 63 (43–123)                 | 170 (81–264)                                                          | 144 (91–222)                                                         | ns       |
| CD8+ T cells         | 465 (316–618)               | 257 (168–445)                                                         | 240 (213–469)                                                         | ns       |
| CD8+ T_Naive cells   | 84 (39–120)                 | 104 (59–198)                                                          | 84 (44–179)                                                           | ns       |
| CD8+ T_EMRA cells    | 349 (271–528)               | 140 (87–277)                                                          | 191 (167–246)                                                         | ns       |
| CD8+ T_EMRA cells    | 15 (9–88)                   | 16 (7–30)                                                             | 25 (13–44)                                                            | ns       |
| CD8+ T_Naive cells   | 110 (59–144)                | 85 (46–188)                                                           | 83 (53–122)                                                           | ns       |
| CD8+ T_EMRA cells    | 151 (85–287)                | 37 (25–69)                                                            | 41 (18–76)                                                            | ns       |
| CD8+CD28null T cells | 228 (85–276)                | 37 (24–86)                                                            | 58 (23–67)                                                            | ns       |
| CD8+CD28null T_mem   | 79 (39–118)                 | 98 (57–175)                                                           | 76 (41–175)                                                           | ns       |
| CD4+ RTL             | 10.20 (9.2–15.2)            | 11.2 (9.1–17.8)                                                       | 12.1 (9.4–14.1)                                                      | ns       |
| CD8+ RTL             | 10.85 (7.7–14)             | 13 (9.7–21.2)                                                         | 11.4 (9.1–16)                                                        | ns       |

Cell numbers are given in cells/μL blood; data represent median (interquartile range).

*When comparing CMV**ESRD patients without to those with CMV-specific CD137+IFNγ+CD4+ T cells.

MEM, memory; CM, central memory; EM, effector memory; EMRA, terminally differentiated effector memory (CD45RA+);
RTL, relative telomere length given as a %; ESRD, end-stage renal disease.
Presence of cellular immunity in the absence of protective antibodies is not uncommon. Possible explanations for this disassociation may be that either cellular immunity is inefficient to induce adequate humoral immunity (6, 7) or that protective antibodies are not adequately maintained. Both these mechanisms may hold true for patients with ESRD. It is known that T-cell dependent vaccines (e.g., HBsAg, tetanus toxoid, and diphtheria) are poor inducers of protective antibody titers in these patients, and antibody titers are poorly maintained (23–25). A detailed analysis of the dynamics and quality of the antigen-specific T cell response after vaccination with HBsAg in ESRD patients showed a poor generation of memory CD4+ T cells (6, 7). In particular, the presence of antigen-specific CD4+ EM T cells correlated significantly with the titers of anti-HBsAg and a similar relation could be shown for anti-CMV IgG. The results of this study also showed a statistically significant relation between the presence of IL-2 or IFNγ-producing CMV-specific CD4+ T cells and anti-CMV IgG ASC. Therefore, a weak induction of a CMV-specific T cell response may underlie the inadequate generation of an anti-CMV humoral response. In addition, it could still be possible that a low but detectable anti-CMV humoral response was generated initially but not adequately maintained.

Although there may be concerns associated with reliably measuring low frequencies of CMV-specific T cells, the multiparameter CD137 flow cytometric assay as described previously (17), allows for a detailed characterization of total pool of antigen-specific T cells which is related with other parameters analyzed within this paper and is associated with clinical outcome, i.e., CMV viremia. The detailed analysis of the CMV-specific response within T cell subsets revealed that CMV-specific memory CD4+ and CD8+ T cells were less differentiated in the CMV-seronegative patients than in CMV-positive patients. This was evident by relatively more CD28+ memory T cells and less CMV-specific T cells producing effector cytokines such as IFNγ and IL-2. Of interest was the detection of a CMV-specific CD137+ response in phenotypically naive T cells that did not produce cytokines. These cells may be part of so-called early branched off memory T cells that are phenotypically naive T cells but are in fact memory T cells in an early developmental stage of which some are able to exert effector function (26). Again this finding supports the concept of a less well-differentiated CMV-specific T-cell response. In this respect, a paper by Redeker et al. (27) nicely illustrated, in a mouse model, the large inter-individual variations in the height of the CMV-specific T cell responses to be dependent on the initial viral load which also influences the extent of memory T-cell inflation and phenotype of CMV-specific T cells. CMV infection generally leads to long-lasting substantial changes in circulating T cells, even more so in ESRD patients (13, 28–31). In particular, highly differentiated EMRA T cells lacking CD28 T cells are expanded in the CD8+ T cell population and to a lesser extent in the CD4+ T cell population (13–15). This typical footprint of CMV infection in the composition of circulating T cells was not found in the CMV-specific T cells of CMV-seronegative patients. This indicates that these patients have encountered CMV but only mounted a limited T cell response. The most likely explanation is low-level of exposure to viral antigens that may not result in the specific imprint induced by high viral antigen exposure which results in sustained CMV-specific IgG serum titers (32, 33). Furthermore, a proportion of CMV-seropositive patients, had no or low frequencies of CMV-specific CD8+ T cells but had CMV-specific CD4+ T cells as well as CMV-IgG-producing cells before transplantation, that were sufficient to prevent from a CMV reactivation. This was in contrast with a paper by Tey et al. that described hematopoietic stem cell transplant recipients, a different group of immunocompromised patients, deficient in reconstituting CMV-specific immunity to have higher viral loads (34). Our data are remarkably consistent with a recent study by Lucia et al. (11) that identified CMV-specific T cell responses in 30% of CMV seronegative individuals. However, their data were generated by ELISpot and therefore lack a more in-depth analysis of the T cell subsets involved. They also claim the detection of CMV-specific memory B cells but frequencies were unfortunately not reported.

In conclusion, assessment of anti-CMV-IgG does not seem to suffice for properly identifying CMV-naïve individuals, as a significant proportion has a weak cellular CMV-specific response, which is associated with protection against CMV viremia after transplantation with a CMV-seropositive donor kidney. We therefore propose to include assessment of cellular immunity in the risk assessment before kidney transplantation. Furthermore, monitoring of CMV-specific cellular immunity following transplantation, i.e., at the end of anti-CMV prophylaxis might be useful for further identifying patients at risk for a CMV viremia, requiring additional antiviral therapy or adjustment of immunosuppressive medication (35).

ETHICS STATEMENT

All patients gave written informed consent to participate in this study. The study was approved by the Medical Ethical Committee of the Erasmus MC (METC number 2010-080) and conducted in accordance with the Declaration of Helsinki and the Declaration of Istanbul.

AUTHOR CONTRIBUTIONS

NL designed the experiments, performed and analyzed the data, and wrote the manuscript; LH, BD, and RM performed the experiments and analyzed the data; JK interpreted the data and edited the manuscript; and MB designed the experiments and edited the manuscript.

FUNDING

This research was financially supported by the Dutch Kidney Foundation (KSPB.10.12) and the China Scholarship Council funding the PhD fellowship of LH (file no: 201307720043).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.01137/full#supplementary-material.
13. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic γ(c,F)+CD4+ T cells in end-stage renal disease. *Kidney Int* (2008) 74(6):760–7. doi:10.1038/kj.2008.301

14. Litjens NH, de Wit EA, Betjes MG. Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets. *Immun Ageing* (2011) 8(1):2. doi:10.1186/1743-4933-8-2

15. Meijers RW, Litjens NH, de Wit EA, Langerak AW, van der Spek A, Baan CC, et al. Cytomegalovirus contributes partly to uraemia-associated premature immunological ageing of the T cell compartment. *Clin Exp Immunol* (2013) 174(3):424–32. doi:10.1111/cei.12188

16. Litjens NH, Huisman M, Baan CC, van Druningen CJ, Betjes MG. Hepatitis B vaccine-specific CD4+ T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers. *Immunol Methods* (2008) 330(1–2):1–11. doi:10.1016/j.imm.2007.10.013

17. Litjens NH, de Wit EA, Baan CC, Betjes MG, Activation-induced CD137 is a fast assay for identification and multi-parameter flow-cytometric analysis of alloreactive T cells. *Clin Exp Immunol* (2013) 174(1):179–191. doi:10.1111/cei.12152

18. Bouvy AP, Kho MM, Klepper M, Litjens NH, Betjes MG, Weimar W, et al. Kinetics of homeostatic proliferation and thrombopoiesis after rATG induction therapy in kidney transplant patients. *Transplantation* (2013) 96(10):904–13. doi:10.1097/TP.0b013e3182a203e4

19. Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH. Premature aging of circulating T cells in patients with end-stage renal disease. *Kidney Int* (2011) 80(2):208–17. doi:10.1038/ki.2011.110

20. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM. Flow cytometry and FISH to measure the average length of telomeres (Flow FISH). *Nat Protoc* (2006) 1(5):265–76. doi:10.1038/nprot.2006.263

21. Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of cytomegalovirus infection. *Curr Opin Immunol* (2009) 21(4):440–5. doi:10.1016/j.coi.2009.05.012

22. Wilkby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. *Exp Gerontol* (2002) 37(2–3):445–53. doi:10.1016/S0531-5565(01)00212-1

23. Cronier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. *Lancet* (1981) 1(8218):455–9.

24. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Sznuzens W. Hepatitis B vaccine in patients receiving haemodialysis. Immunogenicity and efficacy. *N Engl J Med* (1984) 311(8):496–501. doi:10.1056/NEJM198408233110803

25. Girndt M, Piettsch M, Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. *Am J Kidney Dis* (1995) 26(3):454–60.

26. Song K, Rabin RL, Hill BJ, De Rosa SC, Perfetto SP, Zhang HH, et al. Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. *Proc Natl Acad Sci U S A* (2005) 102(22):7916–21. doi:10.1073/pnas.0409720102

27. Redeker A, Welten SP, Arens R. Viral inoculum dose impacts memory T-cell inflation. *Eur J Immunol* (2014) 44(4):1046–57. doi:10.1002/eji.201343946

**REFERENCES**

1. Fiala M, Payne JE, Berne TV, Moore TC, Henle W, Montgomery JZ, et al. Epidemiology of cytomegalovirus infection after transplantation and immunosuppression. *J Infect Dis* (1975) 132(4):421–33. doi:10.1093/infdis/132.4.421

2. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. *J Med Virol* (2013) 85(5):893–8. doi:10.1002/jmv.23539

3. Joniec J, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. *J Exp Med* (1989) 169(4):1199–212. doi:10.1084/jem.169.11.1199

4. Kolars SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. *J Exp Med* (1998) 188(12):2199–204. doi:10.1084/jem.188.12.2199

5. Maloy KJ, Burkhart C, Freer G, Rulicke T, Pircher H, Kono DH, et al. Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection. *J Immunol* (1999) 162(5):2867–74.

6. Litjens NH, Huisman M, Hjirda D, Lambrecht BM, Stittelaar KJ, Betjes MG. IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. *J Immunol* (2008) 181(5):3665–73. doi:10.4049/jimmunol.181.5.3665

7. Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune response and antigen-specific memory CD4+ T cells in hemodialysis patients. *J Am Soc Nephrol* (2008) 19(8):1483–90. doi:10.1681/ASN.2007099971

8. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. *Am J Transplant* (2009) 9(5):1214–22. doi:10.1111/j.1600-6143.2009.02618.x

9. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Nilsson BO, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin Infect Dis* (2013) 56(6):817–24. doi:10.1093/cid/cis593

10. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. *Transplantation* (2003) 76(8):1229–30. doi:10.1097/01.TP.0000083894.61333.56

11. Lucia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llado I, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify frequencies of cytomegalovirus (CMV)-specific memory T and B cells. *Clin Infect Dis* (2014) 59(11):1537–45. doi:10.1093/cid/ciu589

12. Sallusto F, Lanzavecchia A. Functional subsets of CD4+ T lymphocytes. *Curr Top Microbiol Immunol* (2000) 251:167–71.

13. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. *Kidney Int* (2008) 74(6):760–7. doi:10.1038/kj.2008.301
28. Meijers RW, Litjens NH, Hesselink DA, Langerak AW, Baan CC, Betjes MG. Primary cytomegalovirus infection significantly impacts circulating T cells in kidney transplant recipients. *Am J Transplant* (2015) 15(12):3143–56. doi:10.1111/ajt.13396
29. Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JE, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. *Blood* (2001) 98(3):754–61. doi:10.1182/blood.V98.3.754
30. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA. Strong selection of virus-specific cytotoxic CD4+ T cell clones during primary human cytomegalovirus infection. *Blood* (2006) 108(9):3121–7. doi:10.1182/blood-2006-03-006809
31. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim-van Dellen PM, van Lier RA, et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. *J Immunol* (2004) 173(3):1834–41. doi:10.4049/jimmunol.173.3.1834
32. Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. *J Exp Med* (2016) 213(9):1819–34. doi:10.1084/jem.20150598
33. Mayer BT, Krantz EM, Swan D, Ferfenberg J, Simmons K, Selke S, et al. Transient oral human cytomegalovirus infections indicate inefficient viral spread from very few initially infected cells. *J Virol* (2017) 91(12):e00380–17. doi:10.1128/JVI.00380-17
34. Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. *PLoS One* (2013) 8(10):e74744. doi:10.1371/journal.pone.0074744
35. Barabas S, Spindler T, Kiener R, Tonar C, Lugner T, Batzilla J, et al. An optimized IFN-gamma ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. *BMC Immunol* (2017) 18(1):14. doi:10.1186/s12865-017-0195-y

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Litjens, Huang, Dedeoglu, Meijers, Kwekkeboom and Betjes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.